Episode 808
TWiV 808: Clinical update #81 with Dr. Daniel Griffin
September 25, 202151m 39s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #81, Daniel Griffin discusses vaccine boosters, vaccination during pregnancy, mRNA vaccine comparison, J&J vaccine booster, EUA expansion for Lilly monoclonals, remdesivir reduces risk of hospitalization, and anticoagulation regimens.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Pfizer phase III results in 5-11 year olds (Pfizer)
- FDA authorizes booster (FDA)
- V-safe vaccine pregnancy registry (CDC)
- High antibody levels in cord blood (Am J Ob Gyn)
- mRNA vaccines compared (MMWR)
- Effectiveness of single shot J&J (medRxiv)
- J&J booster results (J&J)
- EUA expansion for Lilly mAbs (Lilly)
- Remdesivir reduces hospitalization risk (Gilead)
- DisCoVeRy on Remdesivir (Lancet)
- Prophylactic anticoagulant dosing (Eur Heart J)
- Letters read on TWiV 808
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]